- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00975091
Continue Entecavir Rollover From China
January 29, 2010 updated by: Bristol-Myers Squibb
A Study of the Safety and Antiviral Activity of Open-Label Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Dosing in a Previous Phase II/III Study in China
The purpose of the study is to determine if treatment with entecavir is safe and well tolerated in patients who completed dosing in a previous entecavir study in China, but are requiring further treatment of their chronic hepatitis B virus infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
600
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who had completed the required dosing period in a previous ETV Phase 2 or 3 study in China (studies AI463012, AI463023, AI463056), and had been assessed by the Investigators as likely to benefit from additional therapy for treatment of their HBV infection
- ALT ≤ 15 x upper limit of normal
- Compensated liver disease
Exclusion Criteria:
- Coinfection with HIV, HCV, or HDV
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Entecavir 0.5
|
Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Other Names:
Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Other Names:
|
Active Comparator: Entecavir 1.0
|
Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Other Names:
Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number and percentage of subjects with adverse events, laboratory abnormalities, and discontinuations due to adverse events
Time Frame: Through 3 years of dosing and up to 48 weeks of off treatment follow up
|
Through 3 years of dosing and up to 48 weeks of off treatment follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change in the mean HBV DNA measured by PCR assay from baseline for each entecavir cohort
Time Frame: Through 3 years of dosing
|
Through 3 years of dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Primary Completion (Actual)
August 1, 2007
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
September 8, 2009
First Submitted That Met QC Criteria
September 10, 2009
First Posted (Estimate)
September 11, 2009
Study Record Updates
Last Update Posted (Estimate)
February 2, 2010
Last Update Submitted That Met QC Criteria
January 29, 2010
Last Verified
November 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AI463-050
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B Virus
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Ain Shams UniversityCompleted
-
Bristol-Myers SquibbCompletedChronic Hepatitis B Virus, PediatricUnited States, Korea, Republic of, Taiwan, United Kingdom, Belgium, Canada, Russian Federation, Argentina, Germany, Greece, India, Israel, Poland, Romania
-
California Pacific Medical Center Research InstituteUniversity of California, San FranciscoActive, not recruiting
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bMoldova, Republic of, Ukraine
-
Yangshengtang Co., LtdNot yet recruitingChronic Hepatitis B Virus Infection
-
National Institute of Diabetes and Digestive and...RecruitingChronic Hepatitis B Virus (Hbv)United States
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.RecruitingChronic Hepatitis bChina
-
National Taiwan University HospitalPharmaEssentiaRecruitingChronic Hepatitis B Virus InfectionTaiwan
Clinical Trials on Entecavir
-
Sunshine Lake Pharma Co., Ltd.Suspended
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownLiver Cirrhosis Due to Hepatitis B VirusChina
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People... and other collaboratorsCompleted
-
Taipei Veterans General Hospital, TaiwanBristol-Myers SquibbCompletedProphylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B (HBVNHL)Hepatitis B | Non Hodgkin's LymphomaTaiwan
-
ShuGuang HospitalShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical... and other collaboratorsUnknown
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People... and other collaboratorsCompleted
-
Peking UniversityUnknown
-
National Taiwan University HospitalUnknownHBV/HCV Co-infectionTaiwan
-
Beijing Continent Pharmaceutical Co, Ltd.Completed
-
Taipei Veterans General Hospital, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Changhua Christian...UnknownChronic Hepatitis B